A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess the Tolerability and Safety of Repeated Administrations of a Single-dose of AFFITOPE AD03 to Alzheimer's Disease Patients.
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2011
At a glance
- Drugs Affitope AD03 (Primary) ; Alum
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms MimoVax
- Sponsors AFFiRiS
- 19 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 19 Dec 2011 Actual patient number (28) added as reported by ClinicalTrials.gov.
- 19 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.